INVESTIGADORES
MAZZOLINI RIZZO Guillermo Daniel
artículos
Título:
Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular
Autor/es:
AQUINO J, BOLONTRADE M, GARCIA, M, PODHAJCER OL, MAZZOLINI G
Revista:
GENE THERAPY
Editorial:
NATURE PUBLISHING GROUP
Referencias:
Año: 2010 p. 1 - 17
ISSN:
0969-7128
Resumen:
Mesenchymal stem (stromal) cells (MSCs) are a source
of circulating progenitors that are able to generate cells of
all mesenchymal lineages and to cover cellular demands
of injured tissues. The extent of their transdifferentiation
plasticity remains controversial. Cells with MSC properties
have been obtained from diverse tissues after purification
and expansion in vitro. These cellular populations are
heterogeneous and under certain conditions show pluripotent-
like properties. MSCs present immunosuppressive
and anti-inflammatory features and high migratory capacity
toward inflamed or remodeling tissues. In this study we
review available data regarding factors and signaling axes
involved in the chemoattraction and engraftment of MSCs to
an injured tissue or to a tissue undergoing active remodeling.
Moreover, experimental evidence in support of uses of MSCs
as vehicles of therapeutic genes is discussed. Because of its
regenerative capacity and its particular immune properties,
the liver is a good model to analyze the potential of MSCbased
therapies. Finally, the potential application of MSCs
and genetically modified MSCs in liver fibrosis and hepatocellular
carcinoma (HCC) is proposed in view of available
evidence.in vitro. These cellular populations are
heterogeneous and under certain conditions show pluripotent-
like properties. MSCs present immunosuppressive
and anti-inflammatory features and high migratory capacity
toward inflamed or remodeling tissues. In this study we
review available data regarding factors and signaling axes
involved in the chemoattraction and engraftment of MSCs to
an injured tissue or to a tissue undergoing active remodeling.
Moreover, experimental evidence in support of uses of MSCs
as vehicles of therapeutic genes is discussed. Because of its
regenerative capacity and its particular immune properties,
the liver is a good model to analyze the potential of MSCbased
therapies. Finally, the potential application of MSCs
and genetically modified MSCs in liver fibrosis and hepatocellular
carcinoma (HCC) is proposed in view of available
evidence.